Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab Soravtansine in TNBC
NCT03106077Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mirvetuximab soravtansine in triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate (Metastatic) at 2 years and Pathologic Complete Response / Residual Cancer Burden at 6 months. Started Jun 2017; status: completed.
02
Drugs
mirvetuximab soravtansine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03106077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106077.